257 related articles for article (PubMed ID: 27010145)
21. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Miyoshi M; Mizuno M; Ishiki K; Nagahara Y; Maga T; Torigoe T; Nasu J; Okada H; Yokota K; Oguma K; Tsuji T
J Gastroenterol Hepatol; 2001 Jul; 16(7):723-8. PubMed ID: 11446878
[TBL] [Abstract][Full Text] [Related]
22. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
Suzuki T; Matsuo K; Sawaki A; Wakai K; Hirose K; Ito H; Saito T; Nakamura T; Yamao K; Hamajima N; Tajima K
Epidemiol Infect; 2007 Jan; 135(1):171-6. PubMed ID: 16740190
[TBL] [Abstract][Full Text] [Related]
23. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
[TBL] [Abstract][Full Text] [Related]
24. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study.
Phiphatpatthamaamphan K; Vilaichone RK; Siramolpiwat S; Tangaroonsanti A; Chonprasertsuk S; Bhanthumkomol P; Pornthisarn B; Mahachai V
Asian Pac J Cancer Prev; 2016; 17(4):1903-7. PubMed ID: 27221874
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
26. CYP2C19 polymorphism influences Helicobacter pylori eradication.
Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
[TBL] [Abstract][Full Text] [Related]
27. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
28. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Gawrońska-Szklarz B; Siuda A; Kurzawski M; Bielicki D; Marlicz W; Droździk M
Eur J Clin Pharmacol; 2010 Jul; 66(7):681-7. PubMed ID: 20376628
[TBL] [Abstract][Full Text] [Related]
29. The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole.
Lee JH; Jung HY; Choi KD; Song HJ; Lee GH; Kim JH
Gut Liver; 2010 Jun; 4(2):201-6. PubMed ID: 20559522
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
31. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
[TBL] [Abstract][Full Text] [Related]
32. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Karaca RO; Kalkisim S; Altinbas A; Kilincalp S; Yuksel I; Goktas MT; Yasar U; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):199-206. PubMed ID: 27611887
[TBL] [Abstract][Full Text] [Related]
33. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Tamura T; Kurata M; Inoue S; Kondo T; Goto Y; Kamiya Y; Kawai S; Hamajima N
Nagoya J Med Sci; 2011 Feb; 73(1-2):25-31. PubMed ID: 21614934
[TBL] [Abstract][Full Text] [Related]
34. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Yang JC; Yang YF; Uang YS; Lin CJ; Wang TH
Br J Clin Pharmacol; 2009 May; 67(5):503-10. PubMed ID: 19552744
[TBL] [Abstract][Full Text] [Related]
36. [Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory
Zhang YD; Dong QW; Zhang SH; Gu F; Zhang Y; Song HB; Zuo NY; Zhang SS; Ma L; Ding ZL
Zhonghua Er Ke Za Zhi; 2020 Jan; 58(1):41-45. PubMed ID: 31905475
[No Abstract] [Full Text] [Related]
37. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
Shimoyama T; Chinda D; Sawada Y; Komai K; Chiba H; Saito Y; Sasaki Y; Matsuzaka M; Fukuda S
Intern Med; 2017; 56(13):1621-1627. PubMed ID: 28674348
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
Lee VW; Chau TS; Chan AK; Lee KK; Waye MM; Ling TK; Chan FK
J Clin Pharm Ther; 2010 Jun; 35(3):343-50. PubMed ID: 20831535
[TBL] [Abstract][Full Text] [Related]
39. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
[TBL] [Abstract][Full Text] [Related]
40. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
